These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 19791424)

  • 1. Bortezomib in combination with other therapies for the treatment of multiple myeloma.
    Orlowski RZ
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S16-20. PubMed ID: 19791424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib and its role in the management of patients with multiple myeloma.
    Orlowski RZ
    Expert Rev Anticancer Ther; 2004 Apr; 4(2):171-9. PubMed ID: 15056047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
    Ludwig H; Khayat D; Giaccone G; Facon T
    Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of bortezomib in the treatment of multiple myeloma].
    Gotoh A; Ohyashiki K
    Nihon Rinsho; 2007 Dec; 65(12):2309-14. PubMed ID: 18069278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
    Bladé J; Cibeira MT; Rosiñol L
    Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibition in multiple myeloma.
    Kropff M; Bisping G; Wenning D; Berdel WE; Kienast J
    Eur J Cancer; 2006 Jul; 42(11):1623-39. PubMed ID: 16820291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
    Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
    Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The proteasome: a worthwhile target for the treatment of solid tumours?
    Milano A; Iaffaioli RV; Caponigro F
    Eur J Cancer; 2007 May; 43(7):1125-33. PubMed ID: 17379504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].
    Tobinai K
    Rinsho Ketsueki; 2007 Jun; 48(6):451-7. PubMed ID: 17633092
    [No Abstract]   [Full Text] [Related]  

  • 10. Bortezomib: a novel therapy approved for multiple myeloma.
    Richardson PG; Anderson KC
    Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasome inhibition for treatment of multiple myeloma: clinical update.
    Stadtmauer EA
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
    von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
    Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibition: novel therapy for multiple myeloma.
    Kaufman JL; Lonial S
    Onkologie; 2006 Apr; 29(4):162-8. PubMed ID: 16601373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibition and multiple myeloma.
    Kanagasabaphy P; Morgan GJ; Davies FE
    Curr Opin Investig Drugs; 2007 Jun; 8(6):447-51. PubMed ID: 17621873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibitors in multiple myeloma.
    Anderson KC
    Semin Oncol; 2009 Apr; 36(2 Suppl 1):S20-6. PubMed ID: 19393832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Position statement on the use of bortezomib in multiple myeloma.
    Morgan GJ; Davies FE; Cavenagh JD; Jackson GH; ;
    Int J Lab Hematol; 2008 Feb; 30(1):1-10. PubMed ID: 18190461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibition: a new approach for the treatment of malignancies.
    Spano JP; Bay JO; Blay JY; Rixe O
    Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib.
    Zhou L; Hou J; Fu W; Wang D; Yuan Z; Jiang H
    Leuk Res; 2008 Nov; 32(11):1674-83. PubMed ID: 18485479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins.
    Wolter KG; Verhaegen M; Fernández Y; Nikolovska-Coleska Z; Riblett M; de la Vega CM; Wang S; Soengas MS
    Cell Death Differ; 2007 Sep; 14(9):1605-16. PubMed ID: 17541428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.